Should You Invest in Pfizer in 2022?
Historically, Pfizer (NYSE: PFE) hasn't been a big mover when it comes to stock performance. Over the past 10 years, the S&P 500 Index has outperformed this big pharma company. But momentum is picking up for Pfizer. Last year, it beat the benchmark index -- Pfizer climbed 60%, while the S&P 500 advanced 27%.
And the Pfizer of today doesn't look a lot like the Pfizer of a few years ago. The company in 2020 completed a spinoff of its Upjohn business -- removing an element that had been weighing down revenue. Today, Pfizer has many blockbusters, a new coronavirus treatment on the market, and a full pipeline. So, should you invest in this drugmaker in 2022?
image source: Getty Images.
Source Fool.com
